Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Harvard Medical School and Harvard Pilgrim Health Care Institute | UNKNOWN |
Not provided
Not provided
Not provided
Not provided
This study of current or former cancer patients will evaluate the effect of learning about uncertainties with the benefits of a new cancer drug on their hypothetical decisions to take the drug and their perceptions of the drug's effectiveness.
Many new cancer drugs are approved based on uncertain benefits. Without knowledge of this information, patients may overestimate the benefits of new cancer drugs, resulting in decisions that are not reflective of their individual treatment preferences. A previous study found that learning about uncertainties with a new cancer drug's benefits (such as the drug's small magnitude of effect or limited trial population) reduced the proportion of people who were willing to take the drug. It is unclear whether these findings are generalizable to patients with cancer, who may have different treatment preferences, and may weigh uncertainty about the benefits of new cancer drugs differently from the general public.
In this study, US adults with a current or former cancer diagnosis will be recruited to evaluate the effect of learning about uncertainties with the benefits of a new cancer drug on their hypothetical decisions to take the drug and their perceptions of the drug's effectiveness. Patients will be randomized to 1 of 5 interventions: (1) no uncertainty information (control); or plain-language statements about uncertainties with (2) an unvalidated surrogate endpoint (unknown effect of the drug on survival or quality of life); (3) limited study population (the drug was not studied in patients of similar race or ethnicity); (4) small magnitude of effect (it is unknown whether patients would notice an improvement with the drug), or (5) a combination of all three uncertainties.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Control | Placebo Comparator | No uncertainty information |
|
| Unvalidated surrogate endpoint | Active Comparator | Zenova has only been shown to shrink the size of tumors. It is unknown whether Zenova improves how patients feel or how long they live. |
|
| Limited study population | Active Comparator | Zenova has not been studied in patients similar to Alex (patients with her race and ethnicity). It is unknown whether Zenova will work and what harms it will have for patients like her. |
|
| Small magnitude of effect | Active Comparator | It is unknown whether patients with non-small cell lung cancer will notice an improvement with Zenova. |
|
| Multiple uncertainties | Active Comparator | All 3 statements shown above |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Control | Other | No uncertainty information |
| |
| Unvalidates surrogate endpoint |
| Measure | Description | Time Frame |
|---|---|---|
| Hypothetical decisions | Imagine you were Alex and diagnosed with non-small cell lung cancer. How likely would you be to take the new drug, Zenova?
| Assessed immediately after the intervention |
| Measure | Description | Time Frame |
|---|---|---|
| Perceptions of treatment effectiveness | Imagine you were Alex and diagnosed with non-small cell lung cancer. How likely would you be to take the new drug, Zenova? - Response options: Very unlikely, somewhat unlikely, somewhat likely, very likely | Assessed immediately after the intervention |
| Understanding |
| Measure | Description | Time Frame |
|---|---|---|
| Perceived importance in knowing about uncertainty | Please rate your agreement with the following: The information about Zenova was helpful. Uncertainties about drug benefits and harms should always be communicated. - Response options: Strongly disagree, somewhat disagree, somewhat agree, strongly agree. | Assessed immediately after the intervention |
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Avi Cherla | Contact | 020 7955 7975 | avi_cherla@hphci.harvard.edu |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot_SAP_ICF | Yes | Yes | Yes | Study Protocol, Statistical Analysis Plan, and Informed Consent Form | Jun 17, 2026 | Jun 25, 2026 | Prot_SAP_ICF_000.pdf |
Not provided
| ID | Term |
|---|---|
| D009369 | Neoplasms |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Other |
Zenova has only been shown to shrink the size of tumors. It is unknown whether Zenova improves how patients feel or how long they live. |
|
| Limited study population | Other | Zenova has not been studied in patients similar to Alex (patients with her race and ethnicity). It is unknown whether Zenova will work and what harms it will have for patients like her. |
|
| Small magnitude of effect | Other | It is unknown whether patients with non-small cell lung cancer will notice an improvement with Zenova. |
|
| Multiple uncertainties | Other | All 3 statements shown above |
|
Please rate your agreement with the following statement
|
| Assessed immediately after the intervention |
| Emotions | If you were Alex, how worried would you feel about taking Zenova? - Response options: Very worried, slightly worried, not very worried, not worried at all. | Assessed immediately after the intervention |
| Trust | To what extent do you think the information about Zenova is trustworthy? To what extent do you think the FDA, which approved Zenova and produced this information, is trustworthy? To what extent do you think Alex's doctor, who recommended and prescribed Zenova, is trustworthy? - Response options: Not at all trustworthy, somewhat untrustworthy, somewhat trustworthy, very trustworthy | Assessed immediately after the intervention |